[Skip to Content]
[Skip to Content Landing]
Views 48
Citations 0
Comment & Response
March 29, 2018

Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer

Author Affiliations
  • 1Graduate Education Center, Shandong Academy of Medical Sciences, Jinan, Shandong, China
  • 2Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Cancer Hospital affiliated to Shandong University, Jinan, Shandong, China
JAMA Oncol. Published online March 29, 2018. doi:10.1001/jamaoncol.2018.0228

To the Editor We read with interest the article by Suntharalingam et al1 demonstrating that the addition of cetuximab to concurrent chemoradiation therapy did not improve overall survival in the nonoperative treatment of patients with esophageal cancer. Although the study stratified patients according to tumor histologic type, it was not powered to assess with certainty the benefit of cetuximab therapy in each of the 2 main histological variants of this disease.

First Page Preview View Large
First page PDF preview
First page PDF preview
×